Stemgent
Cambridge
About Stemgent
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $58.4M
- Funding stage: IPO
- Last round: Series Unknown (Aug 2012)
- Ticker: otcpink:SGNI
- Website: stemgent.com
- Phone: +1 (858)550-0934
Industries & Categories
Biotechnology, Human Resources, Search Engine
Social Profiles
Canonical: https://fsome.com/organization/stemgent-1161021 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.